{
    "2019-07-30": [
        [
            {
                "time": "",
                "original_text": "信立泰、石药、正大天晴PK阿斯利康！10亿大品种“1+3”格局形成",
                "features": {
                    "keywords": [
                        "信立泰",
                        "石药",
                        "正大天晴",
                        "阿斯利康",
                        "10亿大品种",
                        "市场竞争"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2019-07-30",
                "original_text": "上海证券市场大宗交易公开信息(2019-07-30)",
                "features": {
                    "keywords": [
                        "上海证券市场",
                        "大宗交易",
                        "公开信息"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "467倍！微芯生物的发行市盈率为何能刷新科创板记录",
                "features": {
                    "keywords": [
                        "微芯生物",
                        "发行市盈率",
                        "科创板",
                        "467倍"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医疗保健：顾盼大分子市场 荐6股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "大分子市场",
                        "荐股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗保健"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "PD-1抑制剂专题报告:百舸争流,PD-1之争谁能胜出",
                "features": {
                    "keywords": [
                        "PD-1抑制剂",
                        "专题报告",
                        "市场竞争",
                        "生物医药"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}